Robbie McNeill receives PhD at 2017 UNC Commencement
Researchers map genetic changes in glioblastoma as it progresses, test potential treatment strategy
May 2, 2017
In a pair of preclinical studies published in the journal Neuro-Oncology, researchers from UNC Lineberger and the Phoenix-based Translational Genomics Research Institute report on the genetic evolution of glioblastoma as it progresses in severity and a potential strategy to treat this often fast-growing brain cancer type.
Read more about this important discovery in at the UNC Lineberger Comprehensive Cancer Center and the Translational Genomics Institute(TGEN).
Robbie McNeill successfully defends graduate thesis
Robert McNeill featured in American Society for Investigative Pathology (ASIP) Trainee Newsletter
February 1, 2017
https://www.asip.org/Trainee_Newsletter/Oct2016/press.cfm
BRAF Mutations Open Doors for N-Ethyl-N-Nitrosourea-Induced Gliomagenesis [Commentary]
Robert S. McNeill, David M. Irvin, and C. Ryan Miller
Am J Pathol 2016, 189:2551-2554
Commentary, published October 2016 in the American Journal of Pathology, written on Short Communication: Wang Q, Satomi K, Oh JE, Hutter B, Brors B, Diessl N, Liu H-K, Wolf S, Otmar S, Wiestler O, Kleihues P, Koelsch B, Kindler-Rohrborn A, Ohgaki H: Braf mutations initiate the development of rat gliomas induced by postnatal exposure to N-ethyl-N-nitrosourea. Am J Pathol 2016, 186:2569-2576
New Glioblastoma Treatment Successfully Tested with Human Cells
February 1, 2017
A new study published today in Science Translational Medicine from the team of Shawn Hingtgen, Ryan Miller, and Matt Ewend at the UNC Eshelman School of Pharmacy and School of Medicine shows that human skin cells converted to neural stem cells deliver therapeutics that inhibit progression of the deadliest adult brain tumor, glioblastoma.
Read more about this important discovery in UNC Spotlights, Lineberger Pathways, at the UNC School of Pharmacy, and at Science Translational Medicine.
Researchers awarded NCI grant to seek new treatments for deadliest adult brain cancer
January 17, 2017
Backed by a three-year, more than $1.8 million grant from the National Cancer Institute, UNC Lineberger researchers Ryan Miller, MD, PhD, and Gary Johnson, PhD, plan to develop better cancer models to identify patterns of drug resistance in glioblastoma.
More information in the LCCC Lineup.
